XML 34 R18.htm IDEA: XBRL DOCUMENT
v3.20.2

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ / shares in Units, $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 18, 2020 | Dec. 19, 2019 | Jul. 31, 2020 | Jul. 23, 2018 | Oct. 19, 2017 | Oct. 31, 2015 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share |  |  |  |  |  |  | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount |  |  |  |  |  |  | 25,997,289 | 7,805,142 | 18,445,764 | 7,812,543
Net proceeds from private placement | $ 41.3 |  |  |  |  |  |  |  |  |
Total proceeds from accounts receivable outstanding |  |  | $ 4.6 |  |  |  |  |  |  |
Total proceeds from accounts receivable outstanding - Chiesi |  |  | 1.6 |  |  |  |  |  |  |
Bio Manguinhos Alfataliglicerase [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Total proceeds from accounts receivable outstanding - Fiocruz |  |  | $ 3.0 |  |  |  |  |  |  |
Private Placement [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ 0.001 |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | 17,604,423 |  |  |  |  |  |  |  |  |
Purchase price (in dollars per share) | $ 2.485 |  |  |  |  |  |  |  |  |
Number of warrants issued (in shares) | 17,604,423 |  |  |  |  |  |  |  |  |
Exercise price of warrants (in dollars per share) | $ 2.36 |  |  |  |  |  |  |  |  |
Exercise of warrants, commencement period | 6 months |  |  |  |  |  |  |  |  |
Term of warrants | 5 years |  |  |  |  |  |  |  |  |
Reverse stock split ratio |  | 1-for-10 |  |  |  |  |  |  |  |
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  |  |  |  |  | 100.00% |  |  |  |
Chiesi US Agreement [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable |  |  |  | $ 25.0 |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  | 20.0 |  |  |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  |  |  | 7.5 |  |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  | $ 760.0 |  |  |  |  |  |
Chiesi US Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  | 15.00% |  |  |  |  |  |
Chiesi US Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  | 40.00% |  |  |  |  |  |
Chiesi Ex US Agreement [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Nonrefundable Non-Creditable Payment Receivable |  |  |  |  | $ 25.0 |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  |  | 25.0 |  |  |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  |  |  |  | 10.0 |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  |  | $ 320.0 |  |  |  |  |
Chiesi Ex US Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 15.00% |  |  |  |  |
Chiesi Ex US Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 35.00% |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share price at which the new stock issued during the period. + References No definition available. + Details
Name: | plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues
Namespace Prefix: | plx_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total proceeds from accounts receivable outstanding - Chiesi. + References No definition available. + Details
Name: | plx_TotalProceedsFromAccountsReceivableOutstandingChiesi
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total proceeds from accounts receivable outstanding - Fiocruz + References No definition available. + Details
Name: | plx_TotalProceedsFromAccountsReceivableOutstandingFiocruz
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNonCreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants
Namespace Prefix: | plx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the proceeds from sale and collection of receivables during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleAndCollectionOfReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=plx_BioManguinhosAlfataligliceraseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |